drugset / Trial / NCT04914377

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants

NCT04914377 ↗

Phase 2 Completed 55 enrolled Novatek Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized (1:1), double-blind, placebo-controlled phase 2 study to assess safety and efficacy of Total TQ Formula (3 g daily dose of Nigella Sativa Oil) capsules versus placebo in treating patients who have tested positive for novel Coronavirus 2019 (Covid-19) in the outpatient setting. Patients will be treated at a dose of 500 mg, 3 capsules, two times a day for 14 days from date of randomization. Quantitative viral load as measured by RT-PCR will be evaluated at baseline and on days 7 and 14. Covid-19 symptoms will be measured throughout the study using Modified FLU-PRO Plus.

Timeline

Start
2021-06-08
Primary completion
2021-12-16
Completion
2022-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject TQ Formula Unknown 3 g Oral

Indications